生物标志物可准确告知局限性前列腺癌的治疗决策。
Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer.
机构信息
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Urology, Singapore General Hospital, Singapore.
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
出版信息
Eur Urol Focus. 2022 May;8(3):643-645. doi: 10.1016/j.euf.2022.03.011. Epub 2022 Mar 23.
PMID:35337775
Abstract
Despite diverse levels of evidence supporting the use of biomarkers at various time points in the management pathway for localised prostate cancer, high-level evidence from prospective head-to-head trials for recommending their routine use to inform treatment decisions is still lacking.
摘要
尽管有不同证据水平支持在局部前列腺癌管理途径的各个时间点使用生物标志物，但仍缺乏前瞻性头对头试验的高级别证据来推荐常规使用这些标志物以告知治疗决策。
Zotero 插件